These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

347 related items for PubMed ID: 15761265

  • 1. Parkin gene therapy for alpha-synucleinopathy: a rat model of Parkinson's disease.
    Yamada M, Mizuno Y, Mochizuki H.
    Hum Gene Ther; 2005 Feb; 16(2):262-70. PubMed ID: 15761265
    [Abstract] [Full Text] [Related]

  • 2. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
    Yamada M, Iwatsubo T, Mizuno Y, Mochizuki H.
    J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Parkin counteracts symptoms in a Drosophila model of Parkinson's disease.
    Haywood AF, Staveley BE.
    BMC Neurosci; 2004 Apr 16; 5():14. PubMed ID: 15090075
    [Abstract] [Full Text] [Related]

  • 6. Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease.
    Kirik D, Annett LE, Burger C, Muzyczka N, Mandel RJ, Björklund A.
    Proc Natl Acad Sci U S A; 2003 Mar 04; 100(5):2884-9. PubMed ID: 12601150
    [Abstract] [Full Text] [Related]

  • 7. Parkin is protective for substantia nigra dopamine neurons in a tau gene transfer neurodegeneration model.
    Klein RL, Dayton RD, Henderson KM, Petrucelli L.
    Neurosci Lett; 2006 Jun 19; 401(1-2):130-5. PubMed ID: 16554120
    [Abstract] [Full Text] [Related]

  • 8. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system.
    Kirik D, Rosenblad C, Burger C, Lundberg C, Johansen TE, Muzyczka N, Mandel RJ, Björklund A.
    J Neurosci; 2002 Apr 01; 22(7):2780-91. PubMed ID: 11923443
    [Abstract] [Full Text] [Related]

  • 9. Nigral overexpression of alpha-synuclein in the absence of parkin enhances alpha-synuclein phosphorylation but does not modulate dopaminergic neurodegeneration.
    Van Rompuy AS, Oliveras-Salvá M, Van der Perren A, Corti O, Van den Haute C, Baekelandt V.
    Mol Neurodegener; 2015 Jun 23; 10():23. PubMed ID: 26099628
    [Abstract] [Full Text] [Related]

  • 10. rAAV-mediated nigral human parkin over-expression partially ameliorates motor deficits via enhanced dopamine neurotransmission in a rat model of Parkinson's disease.
    Manfredsson FP, Burger C, Sullivan LF, Muzyczka N, Lewin AS, Mandel RJ.
    Exp Neurol; 2007 Oct 23; 207(2):289-301. PubMed ID: 17678648
    [Abstract] [Full Text] [Related]

  • 11. Alpha-synuclein overexpression model.
    Mochizuki H, Yamada M, Mizuno Y.
    J Neural Transm Suppl; 2006 Oct 23; (70):281-4. PubMed ID: 17017543
    [Abstract] [Full Text] [Related]

  • 12. Dopaminergic cell loss induced by human A30P alpha-synuclein gene transfer to the rat substantia nigra.
    Klein RL, King MA, Hamby ME, Meyer EM.
    Hum Gene Ther; 2002 Mar 20; 13(5):605-12. PubMed ID: 11916484
    [Abstract] [Full Text] [Related]

  • 13. Down-regulation of alpha-synuclein expression can rescue dopaminergic cells from cell death in the substantia nigra of Parkinson's disease rat model.
    Hayashita-Kinoh H, Yamada M, Yokota T, Mizuno Y, Mochizuki H.
    Biochem Biophys Res Commun; 2006 Mar 24; 341(4):1088-95. PubMed ID: 16460685
    [Abstract] [Full Text] [Related]

  • 14. Overexpression of Parkinson's disease-associated alpha-synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP.
    Dong Z, Ferger B, Feldon J, Büeler H.
    J Neurobiol; 2002 Oct 24; 53(1):1-10. PubMed ID: 12360578
    [Abstract] [Full Text] [Related]

  • 15. Bacterial artificial chromosome transgenic mice expressing a truncated mutant parkin exhibit age-dependent hypokinetic motor deficits, dopaminergic neuron degeneration, and accumulation of proteinase K-resistant alpha-synuclein.
    Lu XH, Fleming SM, Meurers B, Ackerson LC, Mortazavi F, Lo V, Hernandez D, Sulzer D, Jackson GR, Maidment NT, Chesselet MF, Yang XW.
    J Neurosci; 2009 Feb 18; 29(7):1962-76. PubMed ID: 19228951
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons.
    Petrucelli L, O'Farrell C, Lockhart PJ, Baptista M, Kehoe K, Vink L, Choi P, Wolozin B, Farrer M, Hardy J, Cookson MR.
    Neuron; 2002 Dec 19; 36(6):1007-19. PubMed ID: 12495618
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.